Adverse Event Management

T-DM1 Toxicity Management in Breast Cancer

April 05, 2021

Data from the pivotal phase 3 KATHERINE has led to the addition of ado-trastuzumab emtansine to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it.

Preventing Paclitaxel-Related Infusion Reactions

March 24, 2021

Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel.

Patient Perceptions, Other Factors Linked to Fear of Recurrence

February 19, 2021

Fear of cancer recurrence is a common plight for people after they have completed cancer treatment, and recent research analyzed which patient characteristics were associated with higher rates of fear of recurrence.